Polymyalgia Rheumatica (PMR) and Polymyalgia Rheumatica-like (PMR-like) Manifestations in Cancer Patients Following Treatment with Nivolumab and Pembrolizumab: Methodological Blurred Points Identified Through a Systematic Review of Published Case Reports.

Ciro Manzo, Marco Isetta, Alberto Castagna, Melek Kechida

Abstract readSystematic Review

In one paragraph

Synthesis in Medical sciences (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ciro ManzoRheumatologic Outpatient Clinic, Department of Internal and Geriatric Medicine, Azienda Sanitaria Locale Napoli 3, 80065 Sant'Agnello, Italy.ORCID 0000-0002-4800-1817

Marco IsettaLibrary and Knowledge Services, Central and North West London NHS Foundation Trust, London UB8 3NN, UK.

Alberto CastagnaDepartment of Primary Care, Health District of Soverato, Azienda Sanitaria Provinciale Catanzaro, 88100 Catanzaro, Italy.

Melek KechidaDepartment of Internal Medicine and Endocrinology, Fattouma Bourguiba University Hospital, Faculty of Medicine, University of Monastir, Monastir 5000, Tunisia.ORCID 0000-0002-5110-6329

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorsNeoplasmsNivolumabPolymyalgia RheumaticaAgedFemaleHumansMaleAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorsNivolumabpembrolizumabadverse drug reactioncase reportsimmune checkpoints inhibitorsimmunotherapymethodologyNaranjo’s scalenivolumabpembrolizumabpolymyalgia rheumaticasystematic review

Identifiers

PMID40265381

DOI10.3390/medsci13020034

PMCPMC12015857

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.